Welcome to our dedicated page for USANA HEALTH SCIENCES SEC filings (Ticker: USNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
USANA Health Sciences, Inc. filings document financial results, management commentary and Regulation FD disclosures for a health and wellness products company. Form 8-K reports cover quarterly and annual results, preliminary sales information, guidance, exhibits and conference-call materials tied to the company’s operating updates.
Proxy and governance filings address director elections, board matters, executive compensation, equity awards and pay-versus-performance disclosure. Other material-event reports document leadership changes, transition agreements and compensatory arrangements, providing formal records of governance and management structure for USANA Health Sciences.
Noot Walter reported acquisition or exercise transactions in this Form 4 filing.
USANA Health Sciences chief operating officer Walter Noot received a grant of 41,373 restricted stock units on February 19, 2026. Each unit represents the right to receive one share of USANA common stock and vests 25% on each following February 19. After this award, he directly holds 82,552 restricted stock units.
USANA Health Sciences reported that Chief Commercial Officer Brent Neidig acquired 37,610 restricted stock units on February 19, 2026 as a grant. Each unit represents a contingent right to receive one share of USANA common stock. Following this award, Neidig directly holds 74,194 restricted stock units. The grant is scheduled to vest 25% on each February 19 after the grant date.
USANA Health Sciences reported that Chief People Officer Paul A. Jones acquired 25,622 restricted stock units on February 19, 2026 as a grant or award. Each restricted stock unit represents a contingent right to receive one share of USANA common stock. The grant vests in four equal installments of 25% on each February 19 after the grant date. Following this award, Jones holds 51,207 restricted stock units directly.
IIEKKING G DOUG reported acquisition or exercise transactions in this Form 4 filing.
USANA Health Sciences reported that its Chief Financial Officer, Doug G. Iieekking, received a grant of 41,639 restricted stock units on February 19, 2026. Each restricted stock unit represents a contingent right to receive one share of USANA common stock.
The award vests in stages, with 25% of the units vesting on each 19th of February thereafter. Following this grant, the officer directly holds 83,218 restricted stock units, aligning a portion of his compensation with the company’s future share performance.
USANA Health Sciences CEO Kevin Guest reported an equity award. On February 19, 2026, he acquired 82,726 restricted stock units at a stated price of $0.00 per unit. Each unit is a contingent right to receive one share of USANA common stock.
The restricted stock units vest 25% on each 19th of February thereafter under the grant terms. Following this award, Guest directly held a total of 135,062 restricted stock units in USANA.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice reporting proposed dispositions of Common Stock of USNA. The filing lists 4,461 shares across three restricted-stock lots dated 02/06/2026 (1,628), 02/07/2026 (822) and 02/08/2026 (2,011).
USANA Health Sciences reported mixed 2025 results, with revenue up but profits down sharply. Fiscal 2025 net sales rose to $925.3 million from $854.5 million, but net earnings fell to $10.8 million from $42.0 million, and diluted EPS dropped to $0.58 from $2.19. Adjusted diluted EPS declined to $1.93 from $2.59, while Adjusted EBITDA slipped to $101.3 million from $110.3 million.
In Q4 2025, net sales were $226.2 million versus $213.6 million a year earlier, but the company posted a $1.8 million net loss, driven by a $7.0 million non‑cash impairment and $6.5 million of cost‑realignment charges, partly offset by a $3.2 million asset sale gain. Active customers in the core nutritional business declined to 387,000 from 454,000, while Hiya and Rise Wellness delivered strong growth.
For fiscal 2026, USANA guides to modest top-line growth and improved profitability. It projects consolidated net sales between $925 million and $1.0 billion, net earnings of $20.3–$26.6 million, diluted EPS of $1.11–$1.45, adjusted diluted EPS of $1.95–$2.29, and Adjusted EBITDA of $101.3–$109.3 million. The balance sheet shows $158 million of cash and $14 million of debt, after repurchasing 927,000 shares for $28 million in 2025.
USANA Health Sciences filed an amended report to detail compensation changes tied to its CEO transition. Former CEO Jim Brown will serve as a strategic advisor through December 31, 2026, receiving his $825,000 base salary, 2025 bonus, and standard employee benefits during this period.
After his advisory role ends, Brown is entitled to $1,500,000 in severance, paid in three $500,000 installments in 2027, 2028, and 2029, plus 18 months of company-paid COBRA benefits, in exchange for a release of claims and ongoing restrictive covenants. Unvested equity awards at separation will be cancelled.
Returning CEO Kevin Guest will receive an $850,000 base salary, a target annual bonus equal to 100% of salary, a 2026 RSU grant with a $1,700,000 grant date value, and standard benefit and savings plans. He also received a long-term performance award, payable in company shares after a four-year period ending January 1, 2030, if USANA’s stock delivers positive total shareholder return and outperforms the Russell 2000 Index by specified levels, with potential payouts from $850,000 up to $3,400,000.
USANA Health Sciences chief information officer Benedict Peter reported multiple equity transactions in early February 2026. On three dates, restricted stock units converted into common shares at an exercise price of $0, increasing his directly held common stock and reducing his RSU balance.
Across these transactions, some common shares were disposed of at $21.34 per share under transaction code F, leaving Peter with 1,821 shares of USANA common stock and 20,733 restricted stock units held directly after the reported activity.
USANA Health Sciences chief operating officer Walter Noot reported routine equity compensation activity over three days in early February 2026. He exercised restricted stock units (RSUs) into common shares and had a portion of those shares withheld to cover tax obligations at a price of $21.34 per share.
On February 6, 7, and 8, 2026, RSU conversions delivered 3,375, 1,705, and 4,058 common shares, respectively, while 1,609, 813, and 1,738 shares were withheld for taxes. After these transactions, Noot directly held 4,978 shares of common stock and 41,179 RSUs.